Cullinan Therapeutics, Inc.

NasdaqGS:CGEM Stock Report

Market Cap: US$777.8m

Cullinan Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:CGEM Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
24 Feb 26SellUS$52,106Jennifer MichaelsonIndividual3,601US$14.47
24 Feb 26SellUS$52,106Jacquelyn SumerIndividual3,601US$14.47
24 Feb 26SellUS$195,562Nadim AhmedIndividual13,515US$14.47
24 Feb 26SellUS$66,302Jeffrey JonesIndividual4,582US$14.47
20 Feb 26SellUS$50,966Jacquelyn SumerIndividual3,742US$13.62
20 Feb 26SellUS$67,855Jeffrey JonesIndividual4,982US$13.62
20 Feb 26SellUS$50,966Jennifer MichaelsonIndividual3,742US$13.62
20 Feb 26SellUS$59,901Mary FentonIndividual4,398US$13.62
20 Feb 26SellUS$223,109Nadim AhmedIndividual16,381US$13.62
12 Feb 26SellUS$5,004Jennifer MichaelsonIndividual416US$12.03
23 Dec 25SellUS$99,319Nadim AhmedIndividual9,922US$10.01
18 Dec 25SellUS$28,024Jennifer MichaelsonIndividual2,898US$9.67
18 Dec 25SellUS$44,791Jeffrey JonesIndividual4,632US$9.67
18 Dec 25SellUS$33,652Jacquelyn SumerIndividual3,480US$9.67
12 Dec 25SellUS$26,592Jennifer MichaelsonIndividual2,148US$12.38
28 Oct 25BuyUS$1,391,686Lynx1 Capital Management LPCompany165,667US$8.40
17 Oct 25BuyUS$2,103,912Lynx1 Capital Management LPCompany248,749US$8.86
10 Oct 25BuyUS$9,826,941Lynx1 Capital Management LPCompany1,459,641US$7.36

Insider Trading Volume

Insider Buying: CGEM insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of CGEM?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders805,0961.25%
VC/PE Firms7,648,26811.9%
Hedge Funds8,864,81513.8%
Institutions46,905,68973%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 88.27% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.8%
Lynx1 Capital Management LP
8,963,500US$115.2m55.5%21.7%
12.6%
MPM BioImpact LLC
7,648,268US$98.3m0%8.3%
9.5%
BVF Partners L.P.
5,750,683US$73.9m0%2.43%
7.27%
BlackRock, Inc.
4,400,135US$56.5m5.52%no data
5.45%
The Vanguard Group, Inc.
3,298,504US$42.4m12.1%no data
5.15%
Kynam Capital Management, LP
3,114,132US$40.0m35.3%2.59%
3.88%
CHI Advisors LLC
2,350,972US$30.2m-6.37%15.32%
3.63%
State Street Global Advisors, Inc.
2,197,338US$28.2m31%no data
3.19%
Affinity Asset Advisors, LLC
1,932,106US$24.8m632%1.88%
2.82%
RTW Investments, LP
1,705,960US$21.9m0%0.25%
2.28%
VR Management, LLC
1,379,965US$17.7m0%0.6%
2.15%
Geode Capital Management, LLC
1,302,262US$16.7m0.54%no data
2.04%
Boothbay Fund Management, LLC
1,237,043US$15.9m0%0.43%
1.97%
Artal Group S.A.
1,193,410US$15.3m0%0.34%
1.89%
Nextech Invest Ltd.
1,141,145US$14.7m0%1.12%
1.4%
Dimensional Fund Advisors LP
848,769US$10.9m-28.3%no data
1.05%
Great Point Partners, LLC
634,032US$8.1m0%2.49%
1.04%
Renaissance Technologies LLC
631,706US$8.1m19.3%0.01%
1%
Morgan Stanley
607,551US$7.8m120%no data
0.98%
Twin Focus Capital Partners, LLC
595,489US$7.7m0%0.89%
0.97%
Deutsche Asset & Wealth Management
586,636US$7.5m2.61%no data
0.96%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
578,455US$7.4m169%no data
0.78%
Two Sigma Investments, LP
470,526US$6.0m689%0.01%
0.72%
Charles Schwab Investment Management, Inc.
436,273US$5.6m8.35%no data
0.7%
Northern Trust Global Investments
421,635US$5.4m-5.73%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/30 08:34
End of Day Share Price 2026/03/27 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cullinan Therapeutics, Inc. is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Samantha Lynn SemenkowCitigroup Inc
Joshua SchimmerEvercore ISI